In 10 years, NHGRI hopes to take DNA sequencers from the lab to the clinic, but some companies think 10 years isn't soon enough, says Forbes' Matthew Herper. Illumina's Jay Flatley has already talked about getting regulatory approval "to use his technology for medical purposes," Herper says. And even though regulatory approval — whether of the sequencers themselves or the interpretation of the sequence is unclear — is only the first hurdle.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.